New hope for rare blood disorder: ravulizumab trial shows promise in china
NCT ID NCT06578949
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 3 trial tested ravulizumab in 18 adults in China with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study measured changes in LDH, a marker of red blood cell breakdown, to see if the drug could control the disease. All participants had not previously received complement inhibitor treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ravulizumab
- What this could lead to
- If successful, ravulizumab could offer a new treatment option for people with PNH in China, helping control red blood cell destruction and reduce symptoms.
- What could go wrong
- This is a small, single-arm study with only 18 participants, so results may not apply broadly. Ravulizumab requires lifelong treatment and carries infection risks, including meningococcal infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Beijing, CN-100730, China
-
Research Site
Guangzhou, 510100, China
-
Research Site
Hangzhou, 310003, China
-
Research Site
Nantong, 226001, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Tianjin, 300020, China
-
Research Site
Tianjin, 300050, China
-
Research Site
Wuhan, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A pill that could replace infusions for a rare blood disease?
- Every-8-Week shot could simplify PNH treatment
- Real-World test: can a targeted drug keep PNH in check for years?
- New transplant method aims to reduce complications in bone marrow failure patients
- No treatment, just observation: large study looks at PNH blood cells
- New hope for rare blood disorder: Long-Term study of XH-S003 underway